Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C27H30O16 |
Molecular Weight | 610.5175 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 10 / 10 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
C[C@@H]1O[C@@H](OC[C@H]2O[C@@H](OC3=C(OC4=C(C3=O)C(O)=CC(O)=C4)C5=CC=C(O)C(O)=C5)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@H](O)[C@H]1O
InChI
InChIKey=IKGXIBQEEMLURG-NVPNHPEKSA-N
InChI=1S/C27H30O16/c1-8-17(32)20(35)22(37)26(40-8)39-7-15-18(33)21(36)23(38)27(42-15)43-25-19(34)16-13(31)5-10(28)6-14(16)41-24(25)9-2-3-11(29)12(30)4-9/h2-6,8,15,17-18,20-23,26-33,35-38H,7H2,1H3/t8-,15+,17-,18+,20+,21-,22+,23+,26+,27-/m0/s1
DescriptionCurator's Comment: http://phenol-explorer.eu/contents/polyphenol/296 | https://www.ncbi.nlm.nih.gov/pubmed/22731245
Curator's Comment: http://phenol-explorer.eu/contents/polyphenol/296 | https://www.ncbi.nlm.nih.gov/pubmed/22731245
Rutin, also called rutoside, is the glycoside flavonoid found in a certain fruits and vegetables. Most rutine-rich foods are capers, olives, buckwheat (whole grain flour), asparagus, raspberry.In a clinical trial, rutin was found to aid control of intraocular pressure in patients with primary open angle glaucoma. As a component of dietary supplement Phlogenzym, rutin is used for treatment of osteoarthritis. Rutin is also used for treatment of post-surgical swelling of the arm after breast cancer surgery. Traditionally, rutin is used to prevent mucositis due to cancer treatment, to treat blood vessel disease such as varicose veins, bleeding, hemorrhoids.
CNS Activity
Originator
Sources: https://naldc.nal.usda.gov/download/IND43894155/PDF
Curator's Comment: Rutin was first isolated in 1842 by GFerman chemist AUgust Weiss from garden ruc, Ruta graveolens
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2622 Sources: https://www.ncbi.nlm.nih.gov/pubmed/12193020 |
13.0 nM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | PHLOGENZYM Approved UseTaking rutin by mouth in combination with trypsin and bromelain seems to be about as effective as the medication diclofenac (Voltaren) in relieving pain and improving knee function in people with osteoarthritis. |
|||
Primary | WOBENZYM Approved UseSwelling in the arm after breast surgery (post-surgical lymphedema). Some early research suggests that taking a specific product (Wobenzym) containing rutin, pancreatin, papain, trypsin, and chymotrypsin daily for 7 weeks reduces swelling in the arm due to breast removal surgery. |
|||
Primary | Unknown Approved UseUnknown |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
23.5 μg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/11151743/ |
16 mg single, oral dose: 16 mg route of administration: Oral experiment type: SINGLE co-administered: |
QUERCETIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
47.6 μg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/11151743/ |
40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered: |
QUERCETIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
89.9 μg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/11151743/ |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
QUERCETIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
381 μg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/11151743/ |
16 mg single, oral dose: 16 mg route of administration: Oral experiment type: SINGLE co-administered: |
QUERCETIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
636 μg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/11151743/ |
40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered: |
QUERCETIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
1017 μg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/11151743/ |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
QUERCETIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
inconclusive | ||||
no | ||||
no | ||||
no | ||||
no | ||||
weak [IC50 111.5 uM] | ||||
yes [EC50 2.32 uM] | ||||
yes [IC50 27 uM] | ||||
yes [IC50 60.7 uM] | ||||
yes [IC50 7.2 uM] | ||||
yes | ||||
yes | ||||
yes | ||||
yes | ||||
yes |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
yes | ||||
yes | ||||
yes |
Tox targets
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
PubMed
Title | Date | PubMed |
---|---|---|
[Conservative management of lymphedema of the limbs]. | 1991 Aug 4 |
|
Inhibition of HIV-1 integrase by flavones, caffeic acid phenethyl ester (CAPE) and related compounds. | 1994 Aug 3 |
|
Identification and quantification of flavonoids in human urine samples by column-switching liquid chromatography coupled to atmospheric pressure chemical ionization mass spectrometry. | 2000 Apr 1 |
|
Prediction of estrogen receptor agonists and characterization of associated molecular descriptors by statistical learning methods. | 2006 Nov |
|
Screening medicinal plants for the detection of novel antimalarial products applying the inhibition of β-hematin formation. | 2011 Dec 15 |
|
Antiplasmodial activity of flavonol quercetin and its analogues in Plasmodium falciparum: evidence from clinical isolates in Bangladesh and standardized parasite clones. | 2012 Jun |
|
Toxicity of thienopyridines on human neutrophil granulocytes and lymphocytes. | 2013 Jun 7 |
|
Effects of resveratrol and other wine polyphenols on the proliferation, apoptosis and androgen receptor expression in LNCaP cells. | 2014 Jul-Aug |
|
Rutin ameliorates cyclophosphamide induced oxidative stress and inflammation in Wistar rats: role of NFκB/MAPK pathway. | 2015 Apr 25 |
Patents
Sample Use Guides
As a dietary supplement and natural nutrient, rutin is administered orally. For osteoarthritis: 2 tablets of a combination product (Phlogenzym), which contains 100 mg of rutin, 48 mg of trypsin, and 90 mg of bromelain, 3 times daily.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/12193020
Inhibition of aldose reductase from rat lens homogenate was measured using DL-glyceraldehyde as a substrate. The reaction was initiated by addition of NADPH at 30°C. After 30 min the reaction was stopped, and 10mM imidazole was added to convert NADP to a fluorescent product. IC50 for rutin was 13 uM.
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
DSLD |
120 (Number of products:1322)
Created by
admin on Mon Mar 31 17:36:10 GMT 2025 , Edited by admin on Mon Mar 31 17:36:10 GMT 2025
|
||
|
WHO-ATC |
C05CA01
Created by
admin on Mon Mar 31 17:36:10 GMT 2025 , Edited by admin on Mon Mar 31 17:36:10 GMT 2025
|
||
|
WHO-VATC |
QC05CA01
Created by
admin on Mon Mar 31 17:36:10 GMT 2025 , Edited by admin on Mon Mar 31 17:36:10 GMT 2025
|
||
|
DSLD |
1394 (Number of products:104)
Created by
admin on Mon Mar 31 17:36:10 GMT 2025 , Edited by admin on Mon Mar 31 17:36:10 GMT 2025
|
||
|
WHO-VATC |
QC05CA51
Created by
admin on Mon Mar 31 17:36:10 GMT 2025 , Edited by admin on Mon Mar 31 17:36:10 GMT 2025
|
||
|
WHO-ATC |
C05CA51
Created by
admin on Mon Mar 31 17:36:10 GMT 2025 , Edited by admin on Mon Mar 31 17:36:10 GMT 2025
|
||
|
NCI_THESAURUS |
C792
Created by
admin on Mon Mar 31 17:36:10 GMT 2025 , Edited by admin on Mon Mar 31 17:36:10 GMT 2025
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
RUTIN
Created by
admin on Mon Mar 31 17:36:10 GMT 2025 , Edited by admin on Mon Mar 31 17:36:10 GMT 2025
|
PRIMARY | |||
|
28527
Created by
admin on Mon Mar 31 17:36:10 GMT 2025 , Edited by admin on Mon Mar 31 17:36:10 GMT 2025
|
PRIMARY | |||
|
100000090310
Created by
admin on Mon Mar 31 17:36:10 GMT 2025 , Edited by admin on Mon Mar 31 17:36:10 GMT 2025
|
PRIMARY | |||
|
3535
Created by
admin on Mon Mar 31 17:36:10 GMT 2025 , Edited by admin on Mon Mar 31 17:36:10 GMT 2025
|
PRIMARY | |||
|
153-18-4
Created by
admin on Mon Mar 31 17:36:10 GMT 2025 , Edited by admin on Mon Mar 31 17:36:10 GMT 2025
|
PRIMARY | |||
|
5G06TVY3R7
Created by
admin on Mon Mar 31 17:36:10 GMT 2025 , Edited by admin on Mon Mar 31 17:36:10 GMT 2025
|
PRIMARY | |||
|
205-814-1
Created by
admin on Mon Mar 31 17:36:10 GMT 2025 , Edited by admin on Mon Mar 31 17:36:10 GMT 2025
|
PRIMARY | |||
|
61606
Created by
admin on Mon Mar 31 17:36:10 GMT 2025 , Edited by admin on Mon Mar 31 17:36:10 GMT 2025
|
PRIMARY | |||
|
1606503
Created by
admin on Mon Mar 31 17:36:10 GMT 2025 , Edited by admin on Mon Mar 31 17:36:10 GMT 2025
|
PRIMARY | |||
|
CHEMBL226335
Created by
admin on Mon Mar 31 17:36:10 GMT 2025 , Edited by admin on Mon Mar 31 17:36:10 GMT 2025
|
PRIMARY | |||
|
5280805
Created by
admin on Mon Mar 31 17:36:10 GMT 2025 , Edited by admin on Mon Mar 31 17:36:10 GMT 2025
|
PRIMARY | |||
|
SUB10407MIG
Created by
admin on Mon Mar 31 17:36:10 GMT 2025 , Edited by admin on Mon Mar 31 17:36:10 GMT 2025
|
PRIMARY | |||
|
2213
Created by
admin on Mon Mar 31 17:36:10 GMT 2025 , Edited by admin on Mon Mar 31 17:36:10 GMT 2025
|
PRIMARY | |||
|
D012431
Created by
admin on Mon Mar 31 17:36:10 GMT 2025 , Edited by admin on Mon Mar 31 17:36:10 GMT 2025
|
PRIMARY | |||
|
DTXSID3022326
Created by
admin on Mon Mar 31 17:36:10 GMT 2025 , Edited by admin on Mon Mar 31 17:36:10 GMT 2025
|
PRIMARY | |||
|
m9708
Created by
admin on Mon Mar 31 17:36:10 GMT 2025 , Edited by admin on Mon Mar 31 17:36:10 GMT 2025
|
PRIMARY | Merck Index | ||
|
5G06TVY3R7
Created by
admin on Mon Mar 31 17:36:10 GMT 2025 , Edited by admin on Mon Mar 31 17:36:10 GMT 2025
|
PRIMARY | |||
|
4055
Created by
admin on Mon Mar 31 17:36:10 GMT 2025 , Edited by admin on Mon Mar 31 17:36:10 GMT 2025
|
PRIMARY | |||
|
DB01698
Created by
admin on Mon Mar 31 17:36:10 GMT 2025 , Edited by admin on Mon Mar 31 17:36:10 GMT 2025
|
PRIMARY | |||
|
C819
Created by
admin on Mon Mar 31 17:36:10 GMT 2025 , Edited by admin on Mon Mar 31 17:36:10 GMT 2025
|
PRIMARY | |||
|
9500
Created by
admin on Mon Mar 31 17:36:10 GMT 2025 , Edited by admin on Mon Mar 31 17:36:10 GMT 2025
|
PRIMARY | RxNorm | ||
|
9220
Created by
admin on Mon Mar 31 17:36:10 GMT 2025 , Edited by admin on Mon Mar 31 17:36:10 GMT 2025
|
PRIMARY |
ACTIVE MOIETY
METABOLITE (PARENT)
METABOLITE (PARENT)
METABOLITE (PARENT)
METABOLITE (PARENT)
METABOLITE (PARENT)
METABOLITE (PARENT)
METABOLITE (PARENT)
METABOLITE (PARENT)
METABOLITE (PARENT)
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)